{"id":"W1968735621","doi":"10.1016/s1470-2045(15)70027-6","title":"Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Pharmaceuticals; Takeda Oncology; GlaxoSmithKline; Public Health Agency; Astellas Pharma Canada; Novartis; Exelixis; Ministry of Education, Culture, Sports, Science and Technology; Bayer; Bristol-Myers Squibb; AstraZeneca; Pfizer","keywords":"Medicine; Prednisone; Prostate cancer; Abiraterone acetate; Internal medicine; Placebo; Clinical endpoint; Enzalutamide; Androgen deprivation therapy; Clinical trial; Population; Oncology; Cancer; Surgery; Urology; Pathology; Androgen receptor","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001286644,0.002062779,0.003649673,0.0005442221,0.0004274861,0.00102205,0.001052416,0.00193571,0.007460036],"category_scores_gemma":[0.001429903,0.0007440449,0.002316864,0.0004746662,0.001365479,0.00113718,0.0004469595,0.002871356,0.001059272],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006249567,"about_ca_system_score_gemma":0.0008788041,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001301567,"about_ca_topic_score_gemma":0.003075254,"domain_scores_codex":[0.999519,0.0002351589,0.00003220508,0.0000941565,0.00003422533,0.0000853657],"domain_scores_gemma":[0.999471,0.0001645198,0.000126003,0.000038818,0.00003200068,0.0001676236],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9847847,0.002007219,0.0002355314,0.001199105,0.0009434635,0.00003204215,0.00003204199,0.000205232,0.001244217,0.00005704988,0.0004261637,0.008833216],"study_design_scores_gemma":[0.9729249,0.0251459,0.0007590427,0.0000375922,0.000455446,0.00001915495,0.00001375258,0.0001408324,0.0001353826,0.00006900398,0.0002874409,0.0000116399],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.971616,0.0179873,0.0008531749,0.001018053,0.001165199,0.003135421,0.001130574,0.0002728274,0.002821403],"genre_scores_gemma":[0.9807349,0.008119461,0.001362337,0.001340281,0.0006135402,0.002098512,0.000865289,0.0000270916,0.00483858],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007460036,"threshold_uncertainty_score":0.02495629,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09142640043602607,"score_gpt":0.3987588878018678,"score_spread":0.3073324873658417,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}